Detailed price information for Tenaya Therapeutics Inc (TNYA-Q) from The Globe and Mail including charting and trades.

Chief Executive Officer of Tenaya Therapeutics. "Funds from this grant will support our ongoing RIDGE-1 clinical trial of TN-401, a potential best-in-class gene therapy for the treatment of PKP2 ...

Tenaya's Board of Directors approved the repricing ... including options for the company's Chief Medical (TASE:PMCN) Officer, Whit Tingley. The company continues to make strides in its gene ...

Hercules Capital brings a conservative yet flexible BDC strategy and a focus on innovative companies. Read why dividend ...

In a recent 8-K filing with the SEC, Tenaya Therapeutics, Inc. announced the appointment of Mr. Tomohiro Higa as the Interim Principal Accounting Officer (PAO), effective Thursday. Mr. Higa, who has ...

Amid these developments, Tenaya announced the departure of Leone Patterson, its Chief Financial and Business Officer, and is currently seeking a replacement. Despite this, analyst firms such as H ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of diabetic macular edema ...